

This material used at the time of cell processing center (new CPC) tour on March 1, 2018

Regenerative Medicine/Cell Therapy Business Plan (as of March 2018)

Proposed indication, etc.	Partnering	Region (planned)	Cell type	Clinical research	Clinical study
Chronic stroke (SB623)	SanBio	North America	Allo mesenchymal stem cell		In progress (Phase 2b study) ^{*2}
AMD (age-related macular degeneration)	Healios RIKEN	Japan	Allo iPS cell-derived retinal pigment epithelium	In progress	Preparing for start
Parkinson's disease (Designated as a "SAKIGAKE")	Kyoto Univ CiRA	Global	Allo iPS cell-derived dopamine neural progenitor		Plan to start in FY2018 in Japan (Investigator-initiated)
Retinitis pigmentosa	RIKEN	Global	Allo iPS cell-derived photoreceptor	Preparing for start	
Spinal cord injury	Keio Univ Osaka National Hospital	Global	Allo iPS cell-derived neural progenitor	Preparing for start	

Aim to launch in FY2022*1

*1 / Launch schedule is based on our goal that is not agreed with partners.

*2 / Plan to conduct Phase 3 study, but aim to utilize the application of accelerated approval program depending on Phase 2b study result.